Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Barclays PLC

Barclays PLC raised its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 261.4% during the third quarter, HoldingsChannel reports. The firm owned 76,730 shares of the company’s stock after purchasing an additional 55,497 shares during the quarter. Barclays PLC’s holdings in Inozyme Pharma were worth $401,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in shares of Inozyme Pharma by 16.1% during the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after purchasing an additional 26,464 shares during the last quarter. Rhumbline Advisers grew its position in shares of Inozyme Pharma by 22.0% in the second quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock valued at $343,000 after purchasing an additional 13,867 shares during the period. American Century Companies Inc. increased its stake in shares of Inozyme Pharma by 11.0% during the second quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after purchasing an additional 5,673 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Inozyme Pharma in the second quarter valued at approximately $68,000. Finally, Dimensional Fund Advisors LP boosted its stake in Inozyme Pharma by 117.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock worth $1,695,000 after purchasing an additional 205,417 shares during the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on INZY. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Stifel Nicolaus initiated coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target on the stock. Raymond James began coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $17.00.

Inozyme Pharma Trading Up 7.7 %

INZY opened at $3.07 on Friday. Inozyme Pharma, Inc. has a 52 week low of $2.38 and a 52 week high of $7.80. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $3.20 and a 200-day simple moving average of $4.44. The firm has a market cap of $197.22 million, a P/E ratio of -1.97 and a beta of 1.37.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities analysts expect that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.